This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): HY10275
Description: HY10275 is dual-acting histamine H1 and serotonin 5HT2a modulator.
Deal Structure: HY10275 was originally developed by Hypnion using their SCORE bioassay technology, originally licensed from Stanford University.
In March 2007, Eli Lilly and Hypnion announced that the companies have signed a definitive merger agreement whereby Lilly will acquireHypnion. Financial terms of the deal were not disclosed. The acquisition was closed in April 2007.
Additional information available to subscribers only: